ArticleCureus2026
Real-World Effectiveness, Tolerability, and Patient Satisfaction With a Hyaluronic Acid-Based Vaginal Moisturizer in Women With Vaginal Dryness: A Prospective, Multicenter, Observational Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of the study is to evaluate symptom improvement, safety, tolerability, and patient satisfaction associated with a hyaluronic acid-based internal vaginal moisturizer in women with symptomatic vaginal dryness under real-world conditions.
methodsThis prospective, multicenter, single-arm, open-label post-market clinical investigation was conducted in outpatient gynecology clinics in Spain between June and September 2022. Fifty-one women aged ≥18 years with symptomatic vaginal dryness were enrolled; 48 comprised the intention-to-treat population. Participants self-administered a CE-marked hyaluronic acid-based vaginal moisturizer three times weekly for six weeks. The primary endpoint was the change from baseline to week 6 in vaginal dryness severity measured using a non-validated 10-point visual analogue scale (VAS). Secondary endpoints included changes in irritation, itching, dyspareunia, vaginal hydration, vaginal pH, safety, and patient satisfaction. Within-subject changes were analyzed using paired comparisons.
resultsIn participants with paired baseline and week 6 data (n = 47), mean vaginal dryness severity decreased from 7.34 ± 2.20 to 3.47 ± 2.00. The mean change was -3.87 points (95% confidence interval (CI) -4.62 to -3.12; t = -10.5; p < 0.001), corresponding to a large within-subject standardized effect size (Cohen's dz = 1.54). Significant reductions were also observed for irritation (-2.11; n = 47), itching (-2.16; n = 45), and dyspareunia (-2.88; n = 42) (all p < 0.001). Vaginal hydration increased (+2.69; p < 0.001), and vaginal pH decreased modestly (-0.44; p = 0.001). Eight of 48 participants (16.7%) reported device-related adverse events, all mild to moderate; no serious adverse events occurred. Three participants discontinued due to adverse events.
conclusionsIn this prospective, real-world, single-arm clinical investigation, use of a hyaluronic acid-based vaginal moisturizer was associated with significant short-term reductions in vaginal dryness and related symptoms, with an acceptable safety profile. Given the absence of a comparator group, results should be interpreted cautiously. Findings should be considered hypothesis-generating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.